Table 4.
Prediction of Infection in the Thai and US Cohorts
| A. Model Results for the Thai Cohort | B. Model Results for the US Cohort | ||||||
|---|---|---|---|---|---|---|---|
| Model 4 | Estimate | Odds | P Value | Model 4 | Estimate | Odds | P Value |
| Intercept | −17.93 | 0.00 | .00 | Intercept | −25.11 | 0.00 | .00 |
| 1-log increase in NFI at previous visit | 1.29 | 3.63 | .01 | 1-log increase in NFI at previous visit | 0.76 | 2.14 | .32 |
| 1-log increase in NFI at current visit | 1.09 | 2.98 | .01 | 1-log increase in NFI at current visit | 2.38 | 10.85 | .01 |
| Model 5 | Estimate | Odds | P Value | Model 5 | Estimate | Odds | P Value |
| Intercept | −2.85 | 0.06 | .00 | Intercept | −38.33 | 0 | .00 |
| Antibiotics at previous visit | 2.14 | 8.54 | .00 | Antibiotics at previous visit | −8.88 | 0.0001 | .00 |
| Model 6 | Estimate | Odds | P Value | Model 6 | Estimate | Odds | P Value |
| Intercept | −1.27 | 0.28 | .00 | Intercept | −1.77 | 0.17 | .00 |
| Cyclophosphamide at previous visit | −0.34 | 0.71 | .79 | Rituximab at previous visit | 1.35 | 3.84 | .04 |
| Cyclophosphamide at current visit | 1.27 | 3.57 | .17 | Rituximab at current visit | 0.60 | 1.83 | .48 |
The odds of infection based on anti-interferon-γ autoantibody levels (model 1), antibiotic use alone (model 2), and cyclophosphamide or rituximab use (model 3) was assessed using a model that included a term for lagged NFI or treatment (NFI or treatment at a previous visit).
Abbreviation: NFI, neat fluorescence intensity.